Vulnerable patients were less likely to receive subsequent therapies (60% vs 72%), suggesting that supportive care, fitness optimization, and post‑CCRT access may be critical intervention points.
#Oncology #ThoracicOncology #CancerCare #LungCancer #NSCLC #Frailty #CCRT #Cachexia

Serial #CirculatingTumorDNA profiling can stratify risk and predict benefit from consolidation #immunotherapy in limited-stage #SmallCellLungCancer, identifying high-risk patients who gain significant survival advantage from #CCRT plus PD-1 blockade.

#STTT: doi.org/10.1038/s413...

Timing of Durvalumab Consolidation and Survival in Non–Small Cell Lung Cancer: A Population-Based Analysis | JCO Oncology Practice PURPOSEConsolidation durvalumab after concurrent chemoradiation (CCRT) for locally advanced non–small cell lung cancer (NSCLC) extends survival. In the PACIFIC trial, the timing to initiate durvalumab...

Beneficio de añadir durvalumab en pacientes con cáncer de pulmón no microcítico es independiente de iniciarlo en o antes de la semana 4 después de la quimioirradiación #CCRT #durvalumab #NSCLC ascopubs.org/doi/abs/10.1...